The Covid-19 vaccine developed by CanSino Biologics Inc., a company based in Tianjin, China, has become the world’s first nasal vaccine. It does not require any kind of injection. With this announcement, the value of the company’s shares has increased. This is the reason why the company’s shares in Hong Kong have recorded an increase of up to 14.5%.
Ken Sino, head of China’s National Medical Products Administration, said Cansena’s Ad5-nCoV has been approved for emergency use as a booster vaccine, the company said in a statement to the Hong Kong Stock Exchange on Sunday. The vaccine is a new version of Cancina’s one-shot Covid-19 vaccine, which was tested on humans in March 2020.
It should be noted that most of the residents of Shenzhen, the largest technology hub in China, are facing severe problems due to the nationwide lockdown. Because the city of 18 million people is undergoing extensive testing for the Corona virus (COVID-19) and strict measures are being taken to ensure compliance with the lockdown rules. In these circumstances, a single vaccine is being looked at with hope.
A nasal vaccine can stimulate immunity and induce immunity to enhance protection without intramuscular injection, Ken Sino said.from reports by local reporters